Across TCGA pan-cancer cohorts, NPIPA5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NPIPA5 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher NPIPA5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPIPA5 expression acts as an unfavorable survival marker.

PAAD, LUAD, and LIHC are the cancer types where NPIPA5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.112	0.613	<.001	24	view →
LUAD	OS	Median	All	0.237	0.812	.001	15	view →
LIHC	OS	Median	All	0.025	0.777	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NPIPA5 tumor-vs-normal RNA expression · all NPIPA5 data types